摘要
目前国际上已经有数十种正电子显像剂,而只有一种氟标记的正电子放射性药品氟脱氧葡萄糖F18(18F-FDG)已经获得国家注册批准,这大大的限制了正电子放射性药品在中国的发展。本文针对我国正电子放射性药品的注册管理现状,尝试提出科学、合理、规范的正电子放射性药品注册管理的法规建议。
There are over tens of positron-emission tomography(PET)products globally but only a 18F-FDG registered in China,which is a great restriction to develop PET products in China.The paper would like to share some suggestions on China PET product registration management with some analysis about current management situations.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2012年第2期69-72,共4页
Chinese Journal of New Drugs and Clinical Remedies